The important story of Novan — filled with obstacles and opportunities
Jan. 27 was a day Novan executives, its shareholders and its employees wish had never happened. Only four months earlier, the company had started selling shares to the public and in the process raised $52 million. The company, which is developing an acne drug, watched its stock double in a short few weeks and market capitalization reach roughly $500 million.
Then came that chilly Friday in January.
CEO Nate Stasko and his management team were handed results of the Phase 3 trials for the acne drug…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Jennifer Henderson Source Type: news